Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » CytRx s Steven Kriegsman Discusses the Company s Foray into RNAi

CytRx s Steven Kriegsman Discusses the Company s Foray into RNAi

Nov 07, 2003
Premium

At A Glance

Name: Steven Kriegsman

President, CEO — CytRx

Background: Global Genomics, majority shareholder — 2000 Kriegsman Capital Advisors, founder — 1999 The Kriegsman Group, founder — 1992 Kriegsman, Ader, & Co., founder — 1976 BS, accounting, New York University —1964

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Another Protocol Released

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

From Just Some Blood

Time magazine looks into how liquid biopsies are changing cancer care.

Numerous Countries Agree to Vaccine Plan

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

PNAS Papers on Hypertrophic Cardiomyopathy, Major Depression, Spanish SARS-CoV-2 Cat

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

What's Popular?

In Gene Silencing/Gene Editing

  1. Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection

    Premium

  2. JumpCode Genomics Emerges From Stealth Mode With CRISPR-Based Library Prep Kits

    Premium

  3. CRISPR-Chip Maker Cardea Bio Raises $7.5M in First Close of Series A2 Financing Round

  4. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.